BridgeBio Oncology Therapeutics, Inc. Common Stock (BBOT) Stock Price

BBOTStock
$2.82−75.26%52W
Market Cap$226.09M
P/E86.81x
PEG Ratio—
Div yield—
Beta0.77

BBOT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-79.19%
Price vs S&P 500 (4W)-38.16%
VGM Score25.33
P/E Ratio (Annual)86.81x

BBOT Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.54-$0.71-29.95%(-$0.16)
Q4 2025-$0.66-$0.49+25.76%(+$0.17)
Q3 2025-$0.34-$1.03-199.42%(-$0.69)
Q2 2025—-$50.36—

BBOT Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.31
4.31
4.29
4.29

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
BBOTBridgeBio Oncology Therapeutics, Inc. Common Stock
—DF————$2.82
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About BridgeBio Oncology Therapeutics, Inc. Common Stock

BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company developing cancer therapies that target RAS and PI3Ka mutations, two of the most frequently mutated oncogenic drivers. The company aims to address unmet needs in oncology by creating targeted treatments for patients with these genetically-driven cancers.